Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit

Stock Track03-13

Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.

The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.

The legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178275171?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 00:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178275171","market":"sg","top_or_hot":-1,"title":"Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit","media":"Stock Track","content":"<p>Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.</p>\n<p>The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.</p>\n<p>The legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-13 00:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.</p>\n<p>The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.</p>\n<p>The legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"","article_id":"1178275171","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178275171","pubTimestamp":1773331959,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday. The decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗"},"translate_title":"个股追踪|Nektar Therapeutics遭证券集体诉讼盘中暴跌5.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1},"content_text":"Nektar Therapeutics' stock plummeted 5.07% during intraday trading on Thursday.\nThe decline follows news that Pomerantz LLP has filed a securities class action lawsuit against the company and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges that Nektar made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial for alopecia areata treatment.\nThe legal action seeks damages for investors who purchased Nektar securities between February 26, 2025 and December 15, 2025, alleging violations of securities laws. This development creates uncertainty around the company's clinical trial disclosures and potential legal liabilities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178275171","isCrawlerRequest":true}